SCHEMBL8280987

SCHEMBL8280987

NC(Cc1cccc(Cl)c1)C1CCN(C(=O)c2cncnc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.46
ADRB2 P07550 1/20 0.45
HDAC8 Q9BY41 1/20 0.44
DPP4 P27487 6/20 0.43
DPP7 Q9UHL4 4/20 0.42
DPP8 Q6V1X1 2/20 0.42
DPP9 Q86TI2 2/20 0.42
MGLL Q99685 1/20 0.42
F2 P00734 1/20 0.41
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
AKT3 Q9Y243 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM3 P20309 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
KCNH2 Q12809 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8279779 0.90 PKM (0.60) PKMADRB2CHRM2KDM4ELMNA
SCHEMBL8280943 0.87 CHRM2 (0.54) ADRB2HDAC8DPP4MGLLCHRM2
SCHEMBL8281672 0.87 PKM (0.45) PKMADRB2HDAC8DPP4DPP7
SCHEMBL8281671 0.85 PROKR1 (0.46) PKMADRB2HDAC8DPP4MGLL
SCHEMBL14355374 0.83 HDAC8 (0.45) ADRB2HDAC8DPP4DPP7DPP8
SCHEMBL5188797 0.83 HDAC8 (0.45) ADRB2HDAC8DPP4DPP7DPP8
SCHEMBL5571269 0.83 HDAC8 (0.45) ADRB2HDAC8DPP4DPP7DPP8
SCHEMBL14355377 0.83 MEN1 (0.48) HDAC8DPP4DPP9CHRM2MEN1
SCHEMBL8279784 0.82 ADRB2 (0.50) ADRB2HDAC8DPP4DPP7DPP8
SCHEMBL8281654 0.82 RBP4 (0.45) ADRB2HDAC8DPP4DPP7F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265261-A1 Dpp-IV Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-15 US disclosed
US-20070265261-A1 Dpp-IV Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2007-11-15 US disclosed
WO-2005121089-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265261-A1 Dpp-IV Inhibitors DPP4, DPP3, DPP7 PKM 832/4885ADRB2 1332/4885HDAC8 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.